New Zealand made drug firms bid for the whole national market, and prices collapsed

By the early 1990s New Zealand's drug bills kept overrunning, and District Health Boards had to pay the excess out of money meant for hospitals and primary care. The standard approach — reimbursing whatever pharmacies dispensed at posted prices — gave manufacturers all the pricing power.

In 1993 the boards created PHARMAC, a single agency managing one national Pharmaceutical Schedule with a fixed budget. Its cleverest tool is the sole-supply tender: once a drug is off patent, manufacturers bid for a fixed-term contract to supply all or most of the national market. The guaranteed volume is so valuable that even original brand-name makers bid prices down to near-production 'commodity' levels.

A second tool, reference pricing, sets the public subsidy within a therapeutic subgroup at the price of the low-cost alternative; patients who want a pricier option pay the difference themselves, which pressures patented drugs to match tendered prices. Package deals trade listing a new drug for discounts on a firm's other products.

The result: New Zealand kept universal access to necessary medicines while holding spending within budget. A Canada–New Zealand comparison found equivalent drugs priced 21% to 79% lower in New Zealand across the four largest drug classes, implying savings of 50% or more if applied to Canada's system.

Tender the entire national market as one prize

One buyer with one budget faces makers who must deal with it or exit the country

A guaranteed national market is worth a deep price cut to win

Off-patent drugs are interchangeable, so an auction needs no quality judgment

Reference pricing exports the tender price pressure onto patented drugs too

The health boards that fund overruns also capture the savings, so incentives align

A monopsony buyer that can promise the whole market turns sellers' pricing power into a bidding war; exclusivity is the carrot that makes competition work.

PHARMAC still manages the national schedule more than 30 years on, funding roughly 80% of New Zealand's drug expenditure and managing around 2,600 subsidized products. Its model is studied worldwide: the Canada comparison estimated New Zealand-style policies could save Canadian payers 50% or more in established drug classes.